Skip to content

Joseph M. Rootman

University of British Columbia

3 papers in the library · 311 citations · publishing 2021-2022

Papers

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review

BJPsych Open December 23, 2021 Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al. 180 citations

A systematic review of 83 studies found that subanesthetic doses of ketamine produce rapid, short-lived antidepressant and anti-suicidal effects. Evidence for other psychiatric conditions is less robust but suggests similarly positive but transient benefits. The conclusions are tentative due to high risk of bias across the included studies. Optimal dosing, administration methods, and best forms of adjunctive psychotherapy require further investigation.

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

Scientific Reports November 18, 2021 Joseph M. Rootman, Pamela Kryskow, Kalin Harvey et al. 78 citations

Among self-selected users of a mobile app, people who microdose psychedelics (mostly psilocybin, 85%) were similar demographically to non-microdosers but more often reported a history of mental health concerns. Within that group, microdosers had lower levels of depression, anxiety, and stress across genders. Health and wellness motives were the most common reasons for microdosing, especially among women and those with mental health concerns. The findings highlight a need for rigorous longitudinal research on microdosing's mental health effects.

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Scientific Reports June 30, 2022 Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al. 53 citations

A naturalistic observational study followed 953 people who microdosed psilocybin (taking small, non-hallucinogenic doses of psychedelic mushrooms) and 180 non-microdosers for about 30 days. Small to medium improvements in mood and mental health were observed among microdosers, consistent across gender, age, and pre-existing mental health concerns. Older adults showed specific improvements in psychomotor performance. Combining psilocybin with lion's mane mushrooms and niacin did not affect mood or mental health changes, but among older microdosers, this combination was linked to greater psychomotor improvements than psilocybin alone or with lion's mane. These findings add controlled evidence to the growing research on psychedelic microdosing.